Solid solution compositions comprising cannabidiols
The present specification discloses solid solution pharmaceutical compositions comprising hard fats, liquid lipids, and one or more cannabidiols, including a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
1. A solid solution pharmaceutical composition comprising:
a) one or more therapeutic compounds comprising a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, the one or more therapeutic compounds in an amount of less than about 55% by weight of the solid solution pharmaceutical composition;
b) one or more pharmaceutically-acceptable hard fats comprising one or more glycerolipids, the one or more pharmaceutically-acceptable hard fats in an amount of at least 30% by weight of the solid solution pharmaceutical composition;
c) one or more pharmaceutically-acceptable liquid lipids comprising one or more partially hydrolyzed fats, the one or more pharmaceutically-acceptable liquid lipids in an amount of about 1% to about 50% by weight of the solid solution pharmaceutical composition, and
wherein the solid solution pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and has a melting point of 30° C. or higher.
2. The solid solution pharmaceutical composition according to claim 1 , wherein the amount of the one or more therapeutic compounds is about 5% to about 45% by weight of the solid solution pharmaceutical composition.
3. The solid solution pharmaceutical composition according to claim 2 , wherein the amount of the one or more therapeutic compounds is about 5% to about 25% by weight of the solid solution pharmaceutical composition.
4. The solid solution pharmaceutical composition according to claim 2 , wherein the amount of the one or more therapeutic compounds is about 20% to about 45% by weight of the solid solution pharmaceutical composition.
5. The solid solution pharmaceutical composition according to claim 1 , wherein the one or more therapeutic compounds comprise a phytocannabinoid.
6. The solid solution pharmaceutical composition according to claim 1 , wherein the phytocannabinoid comprises a tetrahydrocannabinol, a cannabidiol, a cannabinol, a cannabigerol, a tetrahydrocannabivarin, a cannabidivarin, a cannabichromene, or any combination thereof.
7. The solid solution pharmaceutical composition according to claim 6 , wherein the tetrahydrocannabinol comprises a delta-9-tetrahydrocannabinol, a delta-8-tetrahydrocannabinol, or any combination thereof.
8. The solid solution pharmaceutical composition according to claim 1 , wherein the endocannabinoid comprises an arachidonoylethanolamine, a 2-arachidonoyl glycerol, a 2-arachidonyl glyceryl ether, a N-arachidonoyl-dopamine, a virodhamine, a lysophosphatidylinositol, or a combination thereof.
9. The solid solution pharmaceutical composition according to claim 1 , wherein the synthetic cannabinoid comprises a dimethylheptylpyran, a dronabinol, a levonantradol, a nabilone, a rimonabant, or a combination thereof.
10. The solid solution pharmaceutical composition according to claim 1 , wherein the amount of the one or more pharmaceutically-acceptable hard fats is at least 35% by weight of the solid solution pharmaceutical composition.
11. The solid solution pharmaceutical composition according to claim 10 , wherein the amount of the one or more pharmaceutically-acceptable hard fats is at least 40% by weight of the solid solution pharmaceutical composition.
12. The solid solution pharmaceutical composition according to claim 1 , wherein the amount of the one or more pharmaceutically-acceptable hard fats is about 30% to about 60% by weight of the solid solution pharmaceutical composition.
13. The solid solution pharmaceutical composition according to claim 12 , wherein the amount of the one or more pharmaceutically-acceptable hard fats is about 35% to about 50% by weight of the solid solution pharmaceutical composition.
14. The solid solution pharmaceutical composition according to claim 1 , wherein the one or more glycerolipids comprises a triglyceride with one saturated or unsaturated fatty acid having a carbon length of C 12 -C 24 , two saturated or unsaturated fatty acids each having a carbon length of C 12 -C 24 , or three saturated or unsaturated fatty acids each having a carbon length of C 12 -C 24 .
15. The solid solution pharmaceutical composition according to claim 1 , wherein the one or more glycerolipids comprises a mixture of saturated C 10 -C 18 triglycerides having a melting point of between 41° C. to 45° C.
16. The solid solution pharmaceutical composition according to claim 1 , wherein the amount of the one or more pharmaceutically-acceptable liquid lipids is less than 45% by weight of the solid solution pharmaceutical composition.
17. The solid solution pharmaceutical composition according to claim 16 , wherein the amount of the one or more pharmaceutically-acceptable liquid lipids is about 4% to about 40% by weight of the solid solution pharmaceutical composition.
18. The solid solution pharmaceutical composition according to claim 17 , wherein the amount of the one or more pharmaceutically-acceptable liquid lipids is about 8% to about 30% by weight of the solid solution pharmaceutical composition.
19. The solid solution pharmaceutical composition according to claim 1 , wherein the mixture of one or more partially hydrolyzed fats comprises a mixture of one or more monoglycerides, one or more diglycerides, and one or more triglycerides.
20. The solid solution pharmaceutical composition according to claim 19 , wherein the one or more monoglycerides comprise glyceryl monolinoleate.